EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy

Eva De Backer iD, Florian Van Oers iD, Zwi Berneman, Sébastien Anguille iD

Technology in Cancer Research & Treatment · 2026-06 · 25

DOI: 10.1177/15330338261464315 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 29.06.2026. Verfasst von Eva De Backer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp,…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proteomics, Precision Medicine, Immunotherapy. Die Arbeit nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a heterogeneous and aggressive malignancy with limited therapeutic options and high relapse rates. Despite advances in genomic profiling, many genetic aberrations remain untargetable, and current risk stratification models often fail to predict treatment responses. Proteomics offers a complementary approach by directly measuring protein abundance, post-translational modifications, and protein–protein interactions, providing mechanistic insights into drug resistance, disease progression, and therapeutic vulnerabilities. In this review, we explore the emerging role of proteomics in AML, focusing on its application in biomarker discovery, prediction of drug responses, and identification of novel therapeutic targets. Special attention is given to antigen discovery for immunotherapy, where surface and immunopeptidomics enable the identification of AML-specific antigens and neoepitopes. These insights are critical for the development of antigen-targeted therapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR)-based immunotherapies. Integrating proteomics into a multiomics framework could provide actionable insights for guiding precision medicine and improving AML outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteProteomicsPrecision MedicineImmunotherapyHumansBiomarkers, TumorMolecular Targeted TherapyMultiomics

Stichwörter der Autor:innen

acute myeloid leukemiaimmunotherapymulti-omicsprecision medicineproteomics

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory of Experimental Hematology, Vaccine & Infectious Disease Institute, Faculty of Medicine & Health Sciences, University of Antwerp, Antwerp, Belgium.
  • Division of Hematology, Antwerp University Hospital, Edegem, Belgium.

ORCID-Profile: Eva De Backer, Florian Van Oers, Sébastien Anguille

Zitieren

APA

De Backer, E., Van Oers, F., Berneman, Z., & Anguille, S. (2026). Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261464315

Vancouver

De Backer E, Van Oers F, Berneman Z, Anguille S. Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261464315

BibTeX
@article{DeBacker2026,
  author = {De Backer, Eva and Van Oers, Florian and Berneman, Zwi and Anguille, Sébastien},
  title = {Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  volume = {25},
  doi = {10.1177/15330338261464315}
}
Kostenlos starten →